All In Biotech

Drug Trial Radar · NCT04353492

An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab

A Single-arm, Prospective, Multicentre, Open-label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient-reported Outcomes (PRO) in Patients With Relapsing Multiple Sclerosis (RMS) Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod

Last checked: Nov 20, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

562

Actual

Start

Jul 14, 2020

Primary completion

Oct 9, 2024

Study completion Mar 11, 2025

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 20, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Open-label study to evaluate the effectiveness of treatment with ofatumumab in subjects transitioning from any fumarate-based RMS approved therapy or fingolimod due to breakthrough disease.

Conditions

  • Relapsing Multiple Sclerosis

Interventions

  • OfatumumabBiological

    Subjects will receive ofatumumab injections in an autoinjector (AI) for subcutaneous administration containing 20 mg ofatumumab (50 mg/ml, 0.4 ml content)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Relapse Rate (ARR)Time frame: Up to 96 weeks from baseline

Locations

123 sites in 27 countries. Site status is shown where the registry gives one.

  • Fullerton Neuro and Headache Ctr

    Fullerton, California

  • CU Anschutz Med Campus

    Aurora, Colorado

  • Christiana Care Health Services

    Newark, Delaware

  • Memorial Healthcare System

    Hollywood, Florida

  • Homestead Assoc In Research Inc

    Homestead, Florida

  • Neurology Associates PA

    Maitland, Florida

  • UM Department Of Neurology

    Miami, Florida

  • Negroski Neurology

    Sarasota, Florida

  • Axiom Clinical Research of Florida

    Tampa, Florida

  • University Of South Florida

    Tampa, Florida

  • Premiere Research Institute

    West Palm Beach, Florida

  • Atlanta Neuroscience Institute

    Atlanta, Georgia

  • Georgia Neurology and Sleep Medicine Assoc

    Suwanee, Georgia

  • Johns Hopkins Hospital

    Baltimore, Maryland

  • Cleveland Clinic Foundation

    Las Vegas, Nevada

  • University of New Mexico

    Albuquerque, New Mexico

  • Five Towns Neuroscience Research

    Woodmere, New York

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • Columbus Neuroscience

    Westerville, Ohio

  • Multiple Sclerosis Center of Excellence of OMRF

    Oklahoma City, Oklahoma

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania

  • Baylor College of Medicine

    Houston, Texas

  • Saturn Research Solutions LLC

    Plano, Texas

  • INOVA Medical Group

    Fairfax, Virginia

  • Ascension St Francis Center

    Milwaukee, Wisconsin

  • Novartis Investigative Site

    Buenos Aires, Argentina

  • Novartis Investigative Site

    San Miguel de Tucumán, Argentina

  • Novartis Investigative Site

    Rosario, Santa Fe Province, Argentina

  • Novartis Investigative Site

    Rosario, Santa Fe Province, Argentina

  • Novartis Investigative Site

    New Lambton Heights, New South Wales, Australia

  • Novartis Investigative Site

    Woolloongabba, Queensland, Australia

  • Novartis Investigative Site

    Parkville, Victoria, Australia

  • Novartis Investigative Site

    Linz, Austria

  • Novartis Investigative Site

    Vienna, Austria

  • Novartis Investigative Site

    Vienna, State of Vienna, Austria

  • Novartis Investigative Site

    Linz, Upper Austria, Austria

  • Novartis Investigative Site

    Bruges, Belgium

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Edegem, Belgium

  • Novartis Investigative Site

    Pleven, Bulgaria

Showing 40 of 123 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.